{
  "ticker": "ARWR",
  "company_name": "Arrowhead Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06822790",
      "title": "Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Hypertriglyceridemia",
      "start_date": "2025-04-09",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT04998201",
      "title": "Study of ARO-APOC3 in Adults With Mixed Dyslipidemia",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Mixed Dyslipidemia",
      "start_date": "2021-09-28",
      "completion_date": "2023-08-14",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT04375514",
      "title": "Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Cystic Fibrosis, Pulmonary",
      "start_date": "2020-07-30",
      "completion_date": "2022-05-13",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT05533294",
      "title": "Study of ARO-RAGE in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Asthma",
      "start_date": "2022-11-29",
      "completion_date": "2024-02-08",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT06347003",
      "title": "Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Severe Hypertriglyceridemia",
      "start_date": "2024-07-22",
      "completion_date": "2026-09",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT06209177",
      "title": "Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "IgA Nephropathy",
      "start_date": "2024-04-05",
      "completion_date": "2026-03",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT06138743",
      "title": "Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Myotonic Dystrophy 1",
      "start_date": "2024-03-04",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT02738008",
      "title": "Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Hepatitis B",
      "start_date": "2016-03",
      "completion_date": "2016-12",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT06796426",
      "title": "Treatment Protocol of Plozasiran in Adults and Adolescents With FCS",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Familial Chylomicronemia",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    },
    {
      "nct_id": "NCT07241546",
      "title": "Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "condition": "Asthma",
      "start_date": "2025-12",
      "completion_date": "2028-04",
      "enrollment": 0,
      "sponsor": "Arrowhead Pharmaceuticals"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 7,
      "PHASE2": 16,
      "PHASE1, PHASE2": 14,
      "PHASE1": 12,
      "": 1
    },
    "by_status": {
      "RECRUITING": 10,
      "COMPLETED": 19,
      "TERMINATED": 10,
      "ACTIVE_NOT_RECRUITING": 6,
      "AVAILABLE": 1,
      "NOT_YET_RECRUITING": 1,
      "WITHDRAWN": 3
    },
    "active_trials": 16,
    "completed_trials": 19,
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency",
      "Alpha-1 Antitrypsin Deficiency",
      "Alzheimer Disease, Alzheimer Disease, Early Onset",
      "Amyotrophic Lateral Sclerosis",
      "Asthma",
      "Asthma, Chronic Obstructive Pulmonary Disease",
      "C3 Glomerulopathy, IgA Nephropathy",
      "Chronic Hepatitis B",
      "Clear Cell Renal Cell Carcinoma",
      "Cystic Fibrosis, Pulmonary",
      "Dyslipidemias",
      "Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia",
      "Facio-Scapulo-Humeral Dystrophy",
      "Familial Chylomicronemia",
      "Healthy",
      "Healthy Adult Volunteers",
      "Hepatitis B",
      "Hepatitis B, Chronic",
      "Hepatitis B, Hepatitis D",
      "Homozygous Familial Hypercholesterolemia",
      "Hyperlipidemia; Mixed",
      "Hypertriglyceridemia",
      "Hypertriglyceridemia, Familial Chylomicronemia",
      "Idiopathic Pulmonary Fibrosis",
      "IgA Nephropathy",
      "Mixed Dyslipidemia",
      "Myotonic Dystrophy 1",
      "Non-alcoholic Steatohepatitis",
      "Obesity",
      "Obesity, Diabetes Mellitus, Type 2",
      "Severe Hypertriglyceridemia",
      "Spinocerebellar Ataxia Type 2"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:38.152315",
    "search_query": "Arrowhead Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Arrowhead+Pharmaceuticals,+Inc."
  }
}